NCT00006361

SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck

A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and neck.

Detailed description

OBJECTIVES: * Determine the effect of SU5416 on survival and tumor response in patients with advanced or recurrent squamous cell carcinoma of the head and neck. * Determine the safety and toxicity of SU5416 in these patients. OUTLINE: Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 1 year. PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 1.4 years.

Conditions

• Carcinoma of Unknown Primary
• Head and Neck Cancer
• Non-melanomatous Skin Cancer

Interventions

Type	Name	Description
DRUG	semaxanib

Timeline

• Start date: 2000-12-01
• Primary completion: 2003-01-01
• First posted: 2003-05-30
• Last updated: 2009-12-04

Locations

1 site across 1 country: United States